In this solo episode of AI For Pharma Growth, Dr Andree Bates explains why “we’re doing AI” is not a credible board answer, and why activity, pilots and steering committees are not the same as strategy.

Dr Andree breaks down two common answers leadership teams give when asked about AI strategy.

The first is an inventory of activity: pilots, vendors, headcount, committees and initiatives. The second sounds more rigorous: asking every business unit what they want AI to do, scoring those ideas and working through the list. But both miss the real board question: what are you deciding, on what basis, in what order, and with what expected return?

The episode explores why crowdsourced use cases often become “use case copying” rather than genuine internal innovation. A pain point may be real, and a pilot may work, but that does not mean it is one of the highest-value AI opportunities for the organisation. Without financial modelling, business-unit submissions are only inputs, not prioritisation.

Dr Andree also outlines four structural conditions that explain why AI investment often fails to realise value: the value prioritisation gap, the decision rights gap, the data ownership conflict, and incentive misalignment. These issues are connected, and if they are diagnosed in the wrong order, the strategy usually fails at the next layer.

The core message is clear: boards do not need a list of AI activity. They need a strategy they can govern, with clear priorities, financial assumptions, sequencing, ownership and metrics that can be tested over time.

Topics Covered

Why “we’re doing AI” is not a board answer
Activity, demand and value: the difference that matters
Why business-unit use cases are not strategy
Use case copying and internal innovation theatre
The value prioritisation gap
Decision rights between pilot and production
Data ownership and access conflicts
Incentives, adoption and rational resistance
What finance needs to see before funding AI
What a real board-level AI answer sounds like

Eularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.

If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.

The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.

Details at eularis.com.

If this episode described your situation, send me a LinkedIn DM starting with ‘SENSECHECK’ and two things: the question you’re trying to answer internally, and what’s currently in flight. I’ll reply with what I’d need to see to turn that activity into a defensible plan, and the next step.

About the Podcast

AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.

Dr. Andree Bates LinkedIn | Facebook | X

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

AI For Pharma Growth

E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer